NCT04874311 - Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions

Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma

Interventions

DRUG

Bintrafusp alfa

Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.

DRUG

Doxorubicin

Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles

Trial Locations (8)

NOT_YET_RECRUITING

Institut Paoli Calmette, Marseille

NOT_YET_RECRUITING

Centre Georges François Leclerc, Dijon

WITHDRAWN

IUCT Oncopole, Toulouse

RECRUITING

Institut Bergonie, Bordeaux

RECRUITING

Centre Léon Bérard, Lyon

NOT_YET_RECRUITING

Institut Curie, Paris

RECRUITING

CHU Poitiers, Poitiers

WITHDRAWN

Institut Gustave Roussy, Villejuif